VivaQuant Receives Patent Award for Technique to Remove In-band Noise from ECGs Without Distorting Morphology

Technology cuts in-band noise by 95%. Reduces false positive arrhythmia events, variability of interval measurements, and the cost of extracting and reporting information.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
This latest patent award further supports the company’s vision to position VivaQuant as a world-class provider of ECG processing technology.

St. Paul, MN (PRWEB) February 11, 2014

VivaQuant, LLC announced today that it received an award for US Patent No. 8,632,465 titled “Physiological Signal Denoising”. This patent was invented by Marina Brockway, PhD, Chief Technology Officer of VivaQuant.

A key factor in fast, efficient, and accurate measurement of intervals and detection of arrhythmias in ambulatory ECGs is the ability of the algorithm to grapple with noise caused by electrode movement, muscle noise, and electrical interference. For example, noise in ambulatory ECGs is a major cause of false positive events detected by event recorders and mobile cardiac telemetry. These false positive events can cause errors in reporting, increase cost, and delay diagnosis. A study published in the American Journal of Cardiology and authored by Dr. James Reiffel and collaborators found that 95% of arrhythmia events from an event recorder were falsely detected and therefore contained no information that could lead to a diagnosis. “Removing noise is a big step forward toward improving the accuracy of arrhythmia detection. Removing noise and eliminating its impact on heart beat detection will take us much closer to the holy grail of truly automated evaluations of ambulatory ECGs,” said Dr. Brockway. “This latest patent award further supports the company’s vision to position VivaQuant as a world-class provider of ECG processing technology. Not only is this technology very good at removing noise and detecting QRS complexes in noisy ECGs, it is also extremely computationally efficient, requiring only 100 micro-Watts to process a single-lead ECG in real time.”

This is the fifth issued patent in the VivaQuant ECG processing portfolio and demonstrates its commitment to developing innovative technology that will improve the lives of patients and the productivity and quality of work produced by biomedical researchers.

About VivaQuant, LLC

VivaQuant provides hardware, software and embedded algorithms for processing ECGs. Its Multi-Domain Signal Processing (MDSPTM) technology for ECGs has been shown in research studies to reduce in-band noise by 95%, significantly reduce analysis and reporting labor, and reduce standard deviation of interval measurement variability by up to 5X.

For additional information, visit http://www.VivaQuant.com or, contact Brian at (651) 348-2258, mdsp_info (at) vivaquant (dot) com.


Contact